RxDoctor Payments Data

Jennifer Breedlove, DO

Dermatology · Lima, OHNPI 1528256914

Payments from drug & device makers

$2,188in general payments, 2019–2025

Across 98 payments — averaging $22.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$608
  • Galderma Laboratories, L.p.$351
  • UCB, Inc.$197
  • Regeneron Healthcare Solutions, Inc.$112
  • Johnson & Johnson$112
  • Merz North America, Inc.$108
  • plus $700 from 16 others

What the payments were for

  • Speaking & faculty fees$1507%
  • Food & beverage$2,03893%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,188 in reported general payments places this provider in the 45th percentile of 460 dermatology providers in Ohio.

See all dermatology providers in Ohio

Medicare billing

Part B allowed, 2024
$96,988
Medicare patients
468
Services billed
2,792

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa11$218,504
Dupixent PenDupilumab40$149,206
OtezlaApremilast14$63,774
Clobetasol Propionate64$4,957
Fluocinolone AcetonideFluocinolone/Shower Cap35$2,597
Clindamycin-Benzoyl PeroxideClindamycin Phos/Benzoyl Perox13$2,469
Clindamycin Phosphate51$2,339
Ketoconazole200$2,060
Fluorouracil31$1,940
Sulfacetamide Sodium20$1,665
Desonide18$1,216
Triamcinolone Acetonide116$1,112
Doxycycline Monohydrate16$604
Fluocinonide24$548
ValacyclovirValacyclovir Hcl32$467

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$29$63,77414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 460 dermatology providers in Ohio.

Other dermatology in Lima

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →